Analyzing Moleculin Biotech (NASDAQ:MBRX) and Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) and Moleculin Biotech (NASDAQ:MBRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Incyte and Moleculin Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1	10	10	0	2.43
Moleculin Biotech	1	0	2	0	2.33

Incyte currently has a consensus price target of $104.89, suggesting a potential upside of 10.82%. Moleculin Biotech has a consensus price target of $22.00, suggesting a potential upside of 766.14%. Given Moleculin Biotech’s higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Incyte.

Institutional and Insider Ownership

97.0% of Incyte shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 17.8% of Incyte shares are held by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Incyte and Moleculin Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Incyte	25.03%	26.34%	18.71%
Moleculin Biotech	N/A	N/A	-60.88%

Volatility and Risk

Incyte has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Earnings & Valuation

This table compares Incyte and Moleculin Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14 billion	3.66	$1.29 billion	$6.41	14.77
Moleculin Biotech	N/A	N/A	-$33.56 million	($32.75)	-0.08

Incyte has higher revenue and earnings than Moleculin Biotech. Moleculin Biotech is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Summary

Incyte beats Moleculin Biotech on 11 of the 13 factors compared between the two stocks.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.